-42%

est. 2Y upside i

HealthcareSeries B

Medication & support to beat opioid addiction from home

Rank

#666

Sector

Digital Health, Telemedicine, Addiction Treatment

Est. Liquidity

~3Y

Data Quality

Data: Medium

Ophelia presents a moderate to high-risk, strong upside equity opportunity.

Last updated: March 10, 2026

Bull (30%)+200%

Ophelia leverages its Center of Excellence designation and expanded Medicaid partnerships to rapidly gain market share in underserved OUD populations, accelerating growth to 60%+ YoY. This market leadership and strong payor integration drive a premium exit valuation of $1.2B - $1.5B (3-4x current valuation), resulting in a 200% upside for common shareholders.

Base (55%)+95%

Ophelia maintains its 40% YoY growth by expanding into new states and deepening existing payor relationships, reaching an estimated ~$118M in revenue by 2027. A strategic acquisition or IPO at a consistent revenue multiple of ~6.6x leads to an exit valuation of ~$780M, providing a 95% upside.

Bear (15%)-50%

Increased competition from well-funded incumbents or new entrants, coupled with unforeseen regulatory changes or challenges in clinician recruitment, slows Ophelia's growth to 20% YoY. This leads to a contraction in valuation multiple, resulting in an exit at or below $200M, wiping out a significant portion of common stock value due to the $68M preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $68M in liquidation preferences ahead of common stock, representing 17% of the estimated current valuation.

Dilution Risk

moderate

As a Series AAA company, future funding rounds are possible, which would likely cause further dilution for existing equity holders.

Secondary Liquidity

limited

Secondary liquidity is available for accredited investors on platforms like Nasdaq Private Market and Hiive, but is not broadly accessible to all employees.

Other — 18 roles

View all 18 open roles at Ophelia →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Ophelia's data — designed to show you've done your homework.

  • 1

    “How is Ophelia planning to differentiate itself further and maintain its competitive moat against both direct digital health competitors and potential offerings from large healthcare incumbents like UnitedHealth or CVS Health?”

  • 2

    “Given the company's strong growth and recent Series AAA round, what are the key milestones for revenue and market penetration that the leadership team is focused on achieving in the next 18-24 months, and how will these translate into a potential liquidity event?”

  • 3

    “With $68M in total funding and an estimated current valuation of $400M, what is the company's strategy for managing future dilution, and are there any plans for secondary liquidity events or tender offers for employees in the near future?”

Community

Valuation Sentiment

Our model estimates -42% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.